Corrigendum to “American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction” [Gynecol. Oncol. 115 (2009) 132–134]

✍ Scribed by Kala Visvanathan; Scott M. Lippman; Patricia Hurley; Sarah Temin

• Book ID: 113962362
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 70 KB
• Volume: 116
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2009.12.019